Merith Basey Advocates for Transparency in PBM Practices | AHIP 2024
Merith Basey, M.Sc., executive director of Patients for Affordable Drugs, discusses her group's focus on the monopoly pricing of pharmaceutical companies and bills in Congress addressing patent reform and "pay for delay" strategies, in an interview with MHE previewing the presentation she's co-presenting on June 11 at the AHIP 2024 meeting in Las Vegas.
In an interview conducted before the AHIP 2024 meeting in Las Vegas, June 11-13, Merith Basey, M.Sc., executive director of Patients for Affordable Drugs, discusses her group's focus on the monopoly pricing of pharmaceutical companies and bills in Congress addressing patent reform and "pay for delay" strategies.
But Basey said that "our role and responsibility is to share the facts and that includes calling out the role of PBMs."
At AHIP, Basey co-presented on "Making Prescription Drugs Affordable and Accessible for Everyone," alongside Lauren E. Aronson, executive director, Campaign for Sustainable Rx Drug Pricing; Vin Gupta, M.D., M.S.t, M.P.A., chief medical officer, Amazon Pharmacy and Adam Kautzner, Pharm.D., president, Evernorth Care Management and Express Scripts.
Her team at Patients for Affordable Drugs, which stresses its independence of pharmaceutical companies and their funding, cares about PBM reform, she says, and greater transparency about PBM practices.
"If PBMs are telling us that they are there to serve patients and help negotiate lower prices, our angle is, well, show us the receipts — if that's the case, we'd like to some evidence of that."
Patients Express Concerns Over Costs, Risks of Gene Therapies for Sickle Cell Disease
December 12th 2024Research at the annual meeting of the American Society of Hematology evaluated patient and caregiver perspectives on gene therapies for sickle cell disease, which offer great potential but have had slow uptake.
Read More
Jack Linehan of Epstein Becker Green Discusses Drug Coupons, Accumulators
July 9th 2020In this week's episode of Tuning Into The C-Suite podcast, Senior Editor Peter Wehrwein has a conversation with John "Jack" Linehan, a lawyer for Epstein Becker Green, about coupons and accumulators. Jack is an expert on drug distribution and reimbursement, and few people know as much about coupons and accumulators as he does. Peter and Jack go over some of the basics, who is advantaged and disadvantaged, and then dive into some the details on CMS regulations and how recent proposed changes to Medicaid best price rules would, if finalized, affect coupons and accumulators.
Listen
